>I have been wondering for much longer why nobody sees the value of this company.< Some people do :-) >It seems nowadays that if there is no immediate revenue there is no shareholders’ interest.< Investor fashion can change abruptly. Alternative production platforms could be all the rage a year from now. Moreover, drug companies themselves are paying attention to this arena, as evidenced by MRK’s acquisition of GlycoFi for $400M. My advice is to take a breather from watching the tape. If the fundamentals are strong, the share price will take care of itself in due course.